Dotarem® vs. Gadavist®

Dotarem® vs. Gadavist®

Despite the difference in relaxivity between these 2 GBCAs, there Is No Measurable Difference in Clinical Benefit Observed Between Dotarem® and Gadavist®1  as demonstrated by the Remind Study, a multicenter, double-lined, randomized, controlled intraindividual crossover study.1

Results

For all readers, more than 90% presented with good or excellent overall lesion visualization and characterization with either of the two contrast agents.1

Rate of patients with overall lesion visualization and characterization scored good/excellent or poor/fair

 

Additionally, in most cases there was no preference of the readers for either contrast agent regarding border delineation, internal morphology, and the qualitative degree of contrast enhancement despite quantitative mean lesion percentage enhancement being higher with gadobutrol.1

Border Delineation

Internal Morphology 

Degree of Contrast Enhancement

Case Studies

The REMIND Study demonstrates non-inferiority in lesion visualization and characterization for both Dotarem and Gadavist.1


A 46-year old woman with glioblastoma

 

A 76-year old man with a high-grade glioma

 

Summary

This study “demonstrates the non-inferiority of gadoterate meglumine [Dotarem®] versus gadobutrol [Gadavist®] for overall visualization and characterization of primary brain tumors.”1

  • For all readers in the REMIND Study, more than 90% of patient images were scored with good or excellent overall lesion visualization and characterization with either Dotarem® or Gadavist®.1
  • The REMIND Study also confirmed low incidence of immediate reported AEs with Dotarem® and with Gadavist®, as shown in multiple previous studies.1-3
  • Dotarem® is the first imaging contrast with macrocyclic and ionic structure for high thermodynamic and kinetic stability.4,5
  • Dotarem® is not only trusted for high molecular stability4-5; the REMIND Study demonstrates that it is as effective as Gadavist® for MRI diagnosis of primary brain tumors.1

Download the REMIND Study

References

  1. Maravilla K et al. Comparison of Gadoterate Meglumine and Gadobutrol in the Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study). 2017 June 29. doi: 10:3174/ajnr.A5316. [Epub ahead of print]. 
  2. de Kerviler E et al. Adverse reactions to gadoterate meglumine: review of ov¬oer 25 years of clinical use and more than 50 million doses. Invest Radiol 2016;51:544–51 CrossRef Medline. 
  3. Endrikat J et al. Safety of gadobutrol: results from 42 clinical phase II to IV studies and postmarketing surveillance after 29 million applications. Invest Radiol 2016;51: 537–43 CrossRef Medline. 
  4. Port M et al. Efficiency,thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008;21:469-90. 
  5. Frenzel T et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C. Invest Radiol. 2008;43:817-828.

DOTAREM® is a registered trademark of Guerbet LLC, and is available by prescription only.

Gadavist® is a registered trademark of the Bayer group of companies, and is available by prescription only.